Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2019

01-01-2019 | Images

Compound Heterozygote of Hb D-Punjab and Hb D-Iran; An Interesting Finding

Authors: Preeti Tripathi, Aastha Gupta, Seema Tyagi

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2019

Login to get access

Excerpt

A 29 years-old, primigravida, during antenatal evaluation was referred for Hemoglobin capillary electrophoresis. She was a resident of Delhi and was asymptomatic hitherto. Her physical examination was essentially normal. The blood profile showed hemoglobin (Hb) concentration of 11.3 g/dL, red cell mean corpuscular volume 81.2 fL, mean corpuscular hemoglobin 26.2 pg, mean corpuscular hemoglobin concentration 32.3 g/dL, total red cell count of 4.31 × 106/µL and red cell distribution width of 14.9% (CV). The hemoglobin capillary zone electrophoresis (Minicap Sebia hemoglobin capillary electrophoresis) showed Hb A 0.4%, Hb A2 2.2% and Hb D 97.4% with a bifid peak in D zone (zone D) (Fig. 1a). To further characterize this bifid peak, Hb HPLC (Biorad variant II) was done which showed Hb A 4.10%, Hb D 45.60% and Hb A2 (D Iran) 46.20% with retention times 2.150, 3.620 and 4.002 respectively (Fig. 1b) thereby confirming the patient to be a compound heterozygote of Hb D-Iran and Hb D-Punjab. Her family Hb HPLC study showed her father was heterozygous Hb D-Iran (Fig. 1c), mother to be heterozygous Hb D-Punjab (Fig. 1d) while husband’s Hb HPLC was normal (not shown here). No further fetal testing was done due to insignificant clinical nature of these hemoglobinopathies. This case brings out a rare compound heterozygous encountered in routine screening and further reiterates the significance of combining two modalities of diagnosis in defining hemoglobinopathies.
Metadata
Title
Compound Heterozygote of Hb D-Punjab and Hb D-Iran; An Interesting Finding
Authors
Preeti Tripathi
Aastha Gupta
Seema Tyagi
Publication date
01-01-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1021-2

Other articles of this Issue 1/2019

Indian Journal of Hematology and Blood Transfusion 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine